CYCN - Cyclerion Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
CYCN price evolution
CYCN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.59 | $5.7 | $7.57 | |
| Short term investments | ||||
| Net receivables | $0.04 | |||
| Inventory | ||||
| Total current assets | $3.55 | $4.71 | $6.01 | $8.02 |
| Long term investments | $5.35 | $5.35 | $5.35 | |
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.35 | $5.35 | $5.35 | |
| Total investments | $5.35 | $5.35 | $5.35 | |
| Total assets | $8.9 | $10.06 | $11.36 | $13.37 |
| Current liabilities | ||||
| Accounts payable | $0.3 | $0.65 | $0.74 | $1.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.7 | $1.28 | $1.44 | $2.09 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.7 | $1.28 | $1.44 | $2.09 |
| Shareholders' equity | ||||
| Retained earnings | -$268.02 | -$267.3 | -$265.96 | -$264.42 |
| Other shareholder equity | -$0.02 | -$0.01 | ||
| Total shareholder equity | $8.78 | $9.92 | $11.29 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.57 | $13.38 | $53.96 | $54.4 |
| Short term investments | ||||
| Net receivables | $0.1 | $0.1 | $0.13 | |
| Inventory | ||||
| Total current assets | $8.02 | $14.82 | $55.46 | $58.5 |
| Long term investments | $5.35 | $3.84 | ||
| Property, plant & equipment | $1.22 | $1.47 | $50.27 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.35 | $3.26 | $3.87 | $56.88 |
| Total investments | $5.35 | $3.84 | ||
| Total assets | $13.37 | $18.08 | $59.33 | $115.38 |
| Current liabilities | ||||
| Accounts payable | $1.2 | $2.97 | $1.83 | $1.44 |
| Deferred revenue | ||||
| Short long term debt | $6.8 | |||
| Total current liabilities | $2.09 | $7.63 | $11.09 | $16.95 |
| Long term debt | $38.93 | |||
| Total noncurrent liabilities | $38.93 | |||
| Total debt | $45.73 | |||
| Total liabilities | $2.09 | $7.63 | $11.09 | $55.88 |
| Shareholders' equity | ||||
| Retained earnings | -$264.42 | -$259.15 | -$215.08 | -$163.43 |
| Other shareholder equity | -$0.01 | -$0.02 | -$0.02 | -$0.03 |
| Total shareholder equity | $11.29 | $10.45 | $48.25 | $59.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.19 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.1 | $0.04 | $0.02 | |
| Selling, general & administrative | $1.28 | $1.57 | $1.77 | |
| Total operating expenses | $1.32 | $1.38 | $1.62 | $1.79 |
| Operating income | -$1.38 | -$1.62 | -$1.79 | |
| Income from continuing operations | ||||
| EBIT | -$1.38 | -$1.62 | -$1.79 | |
| Income tax expense | ||||
| Interest expense | $0.04 | -$0.06 | -$0.08 | -$0.1 |
| Net income | ||||
| Net income | -$0.72 | -$1.32 | -$1.54 | -$1.69 |
| Income (for common shares) | -$1.32 | -$1.54 | -$1.69 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.63 | $3.94 | $2.3 | |
| Cost of revenue | ||||
| Gross Profit | $1.63 | $3.94 | $2.3 | |
| Operating activities | ||||
| Research & development | $1.51 | $31.49 | $37.64 | $56.41 |
| Selling, general & administrative | $8.13 | $14.5 | $20.62 | $28.82 |
| Total operating expenses | $12.95 | $46 | $59.14 | $83.56 |
| Operating income | -$12.95 | -$44.37 | -$55.2 | -$81.27 |
| Income from continuing operations | ||||
| EBIT | -$5.62 | -$44.37 | -$51.63 | -$77.8 |
| Income tax expense | ||||
| Interest expense | -$0.36 | -$0.29 | $0.02 | |
| Net income | ||||
| Net income | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| Income (for common shares) | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.32 | -$1.54 | -$1.69 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.18 | $0.18 | $0.1 | |
| Total cash flows from operations | -$1.11 | -$1.87 | -$1.54 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | -$0.01 | -$0 | -$0 | $0 |
| Change in cash and equivalents | -$4.7 | -$1.11 | -$1.88 | -$1.54 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| Operating activities | ||||
| Depreciation | $0.07 | $0.47 | $2.3 | |
| Business acquisitions & disposals | $10.4 | |||
| Stock-based compensation | $1.07 | $6.25 | $9.61 | $14.99 |
| Total cash flows from operations | -$21.25 | -$40.61 | -$36.52 | -$72.49 |
| Investing activities | ||||
| Capital expenditures | $1.46 | $0.02 | ||
| Investments | ||||
| Total cash flows from investing | $10.4 | $1.46 | $0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.02 | $0.03 | $30.79 | $24.58 |
| Net borrowings | $3.51 | |||
| Total cash flows from financing | $5.02 | $0.03 | $30.79 | $28.09 |
| Effect of exchange rate | $0.01 | $0 | $0 | -$0.01 |
| Change in cash and equivalents | -$5.81 | -$40.58 | -$4.27 | -$44.39 |
News
Fundamentals
| Market cap | $8.07M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.53M |
| Revenue | $194.00K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$5.28M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | -68.09% |
| P/E ratio | -1.53 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 41.62 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.09 |
|---|---|
| ROA | -48.34% |
| ROE | N/A |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.07 |
| Quick ratio | N/A |